Skip to main content
SpringerLink
Log in

Neue Einsatzgebiete in der Hausarztpraxis

Wann GLP-1-Analoga, wann SGLT-2-Hemmer verordnen?

Novel indications for GLP-1-analogues and SGLT-2-inhibitors: when should a general practitioner prescribe these agents?

  • FB_Seminar
  • Published:
MMW - Fortschritte der Medizin Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

© ÄZQ, BÄK, KBV und AWMF 2021

Author information

Authors and Affiliations

  1. Department Innere Medizin, Abt. IV Diabetologie, Endokrinologie, Nephrologie, Universitätsklinikum Tübingen, Otfried-Müller-Straße 10, 72076, Tübingen, Germany

    Baptist Gallwitz

Authors
  1. Baptist Gallwitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Baptist Gallwitz.

Ethics declarations

Der Autor war im Zeitraum der letzten 3 Jahre als Referent für folgende Firmen tätig: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Lilly, MSD, NovoNordisk und Sanofi und hat von den folgenden Firmen Honorare als Berater in Advisory Boards erhalten: AstraZeneca, Boehringer Ingelheim, Lilly, MSD, Mylan, Novo Nordisk.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gallwitz, B. Wann GLP-1-Analoga, wann SGLT-2-Hemmer verordnen?. MMW - Fortschritte der Medizin 163, 57–61 (2021). https://doi.org/10.1007/s15006-021-0085-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-021-0085-3

Keywords:

Search

Navigation